Nexalin Technology Reports Persistent Going Concern, Nasdaq Delisting Threat, and Material Weaknesses; Secures $756K via ATM for Clinical Trial
NXL is trading near its 52-week low of $0.33 (5.6% above the low) on light trading volume (0.1× avg).
Summary
Nexalin Technology, Inc. reported a persistent going concern warning, an ongoing Nasdaq delisting threat, and material weaknesses in internal controls, despite raising $756,000 through a dilutive ATM offering and committing $945,000 to a new clinical trial.
Key Events · Earnings and Guidance · NXL
-
Persistent Going Concern Warning
Management explicitly states that the company does not believe it has sufficient cash and cash equivalents to satisfy anticipated cash requirements for the next twelve months, raising substantial doubt about its ability to continue as a going concern.
-
Ongoing Nasdaq Delisting Threat
The company remains non-compliant with Nasdaq's $1.00 minimum bid price rule, having received a deficiency letter on January 21, 2026, with a compliance period extending until July 20, 2026.
-
Material Weaknesses in Internal Controls Persist
The company reported continued material weaknesses in internal control over financial reporting related to a lack of sufficient resources for segregation of duties and insufficient IT controls.
-
Significant Dilutive Capital Raise via ATM Program
During the three months ended March 31, 2026, Nexalin Technology sold 1,395,300 shares of common stock under its ATM program for net proceeds of approximately $756,000. As of March 31, 2026, approximately $2,850,000 remains available under the program.
Analysis · NXL · Industrial Applications And Services
This quarterly report reveals Nexalin Technology, Inc. is in severe financial distress, reiterating a going concern warning and stating that management does not believe it has sufficient cash for the next twelve months. The company continues to face a Nasdaq delisting threat due to non-compliance with the minimum bid price rule, with a compliance deadline of July 20, 2026. Furthermore, material weaknesses in internal controls persist, indicating ongoing operational and financial reporting risks. While the company raised $756,000 through its At-The-Market (ATM) program during the quarter, providing a temporary liquidity boost, this capital raise is highly dilutive and does not resolve the fundamental liquidity issues. The subsequent event of committing $945,000 to a pivotal clinical trial for its HALO Clarity device, while a positive step for product development, adds significant pressure to the company's already strained cash resources. Investors should be highly concerned about the company's ability to continue operations and maintain its listing.
How filings like this one have moved
In the 30 days to Oct 20, 2026, 44.5% of the 283 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NXL was trading at $0.35 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $7.2M. The 52-week trading range was $0.33 to $2.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.